Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy

Inclusion Criteria: Providers must meet all of the following criteria to be eligible for the study: * Be an ophthalmologist with a retinal specialty or with IVT training * Be board-certified by the American Board of Ophthalmology * Be licensed to practice medicine in the state where patients are seen * Be able to conduct physical examinations, including but not limited to ophthalmic examinations, on patients prior to and after injection * Have access to appropriate tools and equipment for pre- and post-injection examinations and monitoring Patients must meet all of the following criteria to be eligible for the study: * Be ≥18 years of age * Have a confirmed diagnosis of neovascular AMD, DME, RVO, or DR (uni- or bilateral) * Have a study eye deemed to be indicated for treatment with SCD411 IVT therapy, as indicated on the US-Eylea label * Be capable of understanding the written informed consent and signed informed consent (patient or legally authorized representative) * Be willing and able to attend all scheduled study visits and comply with protocol requirements Exclusion Criteria: Patients meeting any of the following criteria will not be eligible for the study: * Have active intraocular or periocular infection or active intraocular inflammation (grade: trace or above) in the study eye at Baseline, which is of clinical significance according to the investigator's (HCP's) judgment, such as active infections of the anterior segment; this includes conjunctivitis (except …